Metolazone and Azosemide, Clinically Utilized Diuretics, Exhibit Inhibitory Activity for Glyoxalase I
Biotechnology and Applied Biochemistry · 2025
DOI: 10.1002/bab.2760 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, 2025. Verfasst von Masahiro Watanabe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Shujitsu University, Okayama, Japan. Hauptthemen laut MEDLINE: Lactoylglutathione Lyase, Diuretics, Enzyme Inhibitors. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, JSPS KAKENHI.
Abstract (Originalsprache)
Methylglyoxal (MGO), a byproduct produced in the process of glycolysis, has cytotoxicity and forms advanced glycation endproducts (AGEs), which cause cell failure in several tissues. Because MGO is mainly removed by the action of glyoxalase I (GLO1), the activity of this enzyme contributes to the accumulation of MGO. We recently found that quinetazone, a diuretic pharmaceutical agent, has the potential to inhibit GLO1 activity. Therefore, we explored whether diuretics that have a similar structure to quinetazone inhibit GLO1. The inhibitory characteristics of diuretics with recombinant GLO1 were spectrophotometrically determined. Cell proliferation and accumulation of MGO‐derived AGEs were evaluated by MTT assay and Western blotting. Among the thiazide, thiazide‐like, and loop diuretics, metolazone and azosemide were found to inhibit GLO1 activity by 97% at 100 µM. Furthermore, we examined whether the substructures of these diuretics have inhibitory activity, quinazolinone or phenyltetrazole were determined to be the minimal structures of metolazone or azosemide required for inhibition of GLO1, respectively. In proximal renal tubule‐like HK‐2 and vascular endothelial cell‐like EA.hy926 cells, these diuretics were shown to inhibit cell proliferation and induce accumulation of MGO‐derived AGEs. In contrast, the substructures of these diuretics that did not affect GLO1 activity did not cause these changes. Metolazone and azosemide have inhibitory effects against GLO1. Considering that these diuretics are clinically employed as pharmaceutical agents, high or prolonged dosages may contribute to pathogenesis through GLO1 inhibition, followed by MGO and/or AGE accumulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, Shujitsu University, Okayama, Japan.
- Department of Pharmacology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.
- Department of Translational Research and Drug Development, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
ORCID-Profile: Omer Faruk Hatipoglu, Shuji Mori
Förderung
- Japan Society for the Promotion of Science
- JSPS KAKENHI
Zitieren
APA
Watanabe, M., Toyomura, T., Wake, H., Nishinaka, T., Hatipoglu, O. F., Takahashi, H., Nishibori, M., & Mori, S. (2025). Metolazone and Azosemide, Clinically Utilized Diuretics, Exhibit Inhibitory Activity for Glyoxalase I. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2760
Vancouver
Watanabe M, Toyomura T, Wake H, Nishinaka T, Hatipoglu OF, Takahashi H, et al. Metolazone and Azosemide, Clinically Utilized Diuretics, Exhibit Inhibitory Activity for Glyoxalase I. Biotechnology and Applied Biochemistry. 2025. doi:10.1002/bab.2760
BibTeX
@article{Watanabe2025,
author = {Watanabe, Masahiro and Toyomura, Takao and Wake, Hidenori and Nishinaka, Takashi and Hatipoglu, Omer Faruk and Takahashi, Hideo and Nishibori, Masahiro and Mori, Shuji},
title = {Metolazone and Azosemide, Clinically Utilized Diuretics, Exhibit Inhibitory Activity for Glyoxalase I},
journal = {Biotechnology and Applied Biochemistry},
year = {2025},
doi = {10.1002/bab.2760}
}
EUVIMED